Cosette patents expiration
1. Azor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5616599 | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Apr, 2016
(8 years ago) | |
|
US5616599 (Pediatric) | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Oct, 2016
(7 years ago) | |
Drugs and Companies using AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL ingredient
Market Authorisation Date: 26 September, 2007
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
AZOR family patents
2. Benicar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5616599 | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Apr, 2016
(8 years ago) | |
|
US5616599 (Pediatric) | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Oct, 2016
(7 years ago) | |
| US6878703 | COSETTE | Pharmaceutical composition |
Nov, 2021
(2 years ago) | |
|
US6878703 (Pediatric) | COSETTE | Pharmaceutical composition |
May, 2022
(1 year, 11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 04, 2013 |
| Pediatric Exclusivity(PED) | Aug 04, 2013 |
Drugs and Companies using OLMESARTAN MEDOXOMIL ingredient
Market Authorisation Date: 25 April, 2002
Treatment: Use as an antihypertensive agent; Treatment of hypertension
Dosage: TABLET;ORAL
BENICAR family patents
3. Benicar Hct patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5616599 | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Apr, 2016
(8 years ago) | |
|
US5616599 (Pediatric) | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Oct, 2016
(7 years ago) | |
| US6878703 | COSETTE | Pharmaceutical composition |
Nov, 2021
(2 years ago) | |
|
US6878703 (Pediatric) | COSETTE | Pharmaceutical composition |
May, 2022
(1 year, 11 months ago) | |
Drugs and Companies using HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL ingredient
Market Authorisation Date: 05 June, 2003
Treatment: Use as an antihypertensive agent; Treatment of hypertension
Dosage: TABLET;ORAL
BENICAR HCT family patents
4. Effient patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5288726 | COSETTE | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
Apr, 2017
(7 years ago) | |
|
US5288726 (Pediatric) | COSETTE | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
Oct, 2017
(6 years ago) | |
| US6693115 | COSETTE | Acid addition salts of hydropyridine derivatives |
Jul, 2021
(2 years ago) | |
| US8404703 | COSETTE | Medicinal compositions containing aspirin |
Mar, 2022
(2 years ago) | |
| US8569325 | COSETTE | Method of treatment with coadministration of aspirin and prasugrel |
Jan, 2023
(1 year, 4 months ago) | |
|
US8569325 (Pediatric) | COSETTE | Method of treatment with coadministration of aspirin and prasugrel |
Jul, 2023
(10 months ago) | |
|
US8404703 (Pediatric) | COSETTE | Medicinal compositions containing aspirin |
Jul, 2023
(10 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-182) | Jul 12, 2019 |
| Pediatric Exclusivity(PED) | Jan 12, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jul 10, 2014 |
Drugs and Companies using PRASUGREL HYDROCHLORIDE ingredient
NCE-1 date: 12 January, 2019
Market Authorisation Date: 10 July, 2009
Treatment: Treatment or prophylaxis of thrombosis or embolisms; Use of prasugrel and aspirin in patients requiring the reduction of thrombotic cardiovascular events
Dosage: TABLET;ORAL
EFFIENT family patents
5. Evoxac patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5340821 | COSETTE | Composition and method for treating Sjoegren syndrome disease |
Jul, 2013
(10 years ago) | |
Drugs and Companies using CEVIMELINE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 January, 2000
Treatment: Treating sjoegren syndrome
Dosage: CAPSULE;ORAL
EVOXAC family patents
6. Tribenzor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5616599 | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Apr, 2016
(8 years ago) | |
|
US5616599 (Pediatric) | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Oct, 2016
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 23, 2013 |
Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL ingredient
Market Authorisation Date: 23 July, 2010
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
TRIBENZOR family patents
7. Welchol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7101960 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(10 years ago) | |
| US5917007 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(10 years ago) | |
| US5679717 | COSETTE | Method for removing bile salts from a patient with alkylated amine polymers |
Apr, 2014
(10 years ago) | |
| US6784254 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(10 years ago) | |
| US5919832 | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Jun, 2014
(9 years ago) | |
| US6433026 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Jun, 2014
(9 years ago) | |
| US6066678 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Jun, 2014
(9 years ago) | |
| US5607669 | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Jun, 2014
(9 years ago) | |
|
US5679717 (Pediatric) | COSETTE | Method for removing bile salts from a patient with alkylated amine polymers |
Oct, 2014
(9 years ago) | |
|
US5917007 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(9 years ago) | |
|
US6784254 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(9 years ago) | |
|
US7101960 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(9 years ago) | |
| US5693675 | COSETTE | Alkylated amine polymers |
Dec, 2014
(9 years ago) | |
|
US6433026 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Dec, 2014
(9 years ago) | |
|
US6066678 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Dec, 2014
(9 years ago) | |
|
US5919832 (Pediatric) | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Dec, 2014
(9 years ago) | |
|
US5607669 (Pediatric) | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Dec, 2014
(9 years ago) | |
|
US5693675 (Pediatric) | COSETTE | Alkylated amine polymers |
Jun, 2015
(8 years ago) | |
| US7229613 | COSETTE | Method for lowering serum glucose |
Apr, 2022
(2 years ago) | |
|
US7229613 (Pediatric) | COSETTE | Method for lowering serum glucose |
Oct, 2022
(1 year, 6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-608) | Oct 02, 2012 |
| Pediatric Exclusivity(PED) | Apr 02, 2013 |
Drugs and Companies using COLESEVELAM HYDROCHLORIDE ingredient
Market Authorisation Date: 26 May, 2000
Treatment: Use as a bile acid sequestrant for lowering cholesterol; Use as a bile acid sequestrant; Treatment of type 2 diabetes mellitus
Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL; CAPSULE;ORAL; BAR, CHEWABLE;ORAL
WELCHOL family patents